Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873020 | 0.76 | CYP19A1 (0.59) | CNR1CYP19A1CYP11B1CNR2KEAP1 | |
| SCHEMBL3873345 | 0.75 | CYP19A1 (0.59) | CYP19A1CYP11B1KEAP1 | |
| SCHEMBL9681284 | 0.74 | CYP19A1 (0.49) | CNR1CYP19A1CYP11B1CNR2KEAP1 | |
| SCHEMBL8884360 | 0.74 | CYP19A1 (0.60) | CYP19A1CYP11B1KEAP1 | |
| SCHEMBL9026711 | 0.73 | CYP19A1 (0.58) | CYP19A1CYP11B1KEAP1 | |
| SCHEMBL14092714 | 0.73 | CNR1 (0.41) | CNR1CYP19A1CYP11B1KEAP1 | |
| SCHEMBL18546891 | 0.73 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL17557655 | 0.72 | CNR1 (0.63) | CNR1CNR2 | |
| Bromide SCHEMBL8884686 | 0.72 | CYP19A1 (0.57) | CYP19A1CYP11B1KEAP1 | |
| SCHEMBL18547458 | 0.72 | CNR1 (0.45) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874304-B1 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-15 | — | — | EP | claimed |
| US-20080194656-A1 | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194656-A1 | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194656-A1 | Benzotriazole Derivatives as Cannabinoid Receptor Antagonists | CNR1, CNR2, HTR3C | CNR1 1/4885CYP19A1 1108/4885CYP11B1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.